PHARMACY

NABP recommends state boards of pharmacy to require PTCB certification

BY Drug Store News Team

NEW YORK The Pharmacy Technician Certification Board welcomed a recommendation this week by the National Association of Board of Pharmacy that state boards of pharmacy require pharmacy technicians to have PTCB certification. The NABP will amend its Model Act to recommend that all boards of pharmacy require pharmacy tech certification by 2015.

 

A uniform, nationwide pharmacy tech testing and certification system like the one the NABP recommends will ensure that pharmacy techs throughout the country are held to the same standard and thus ensure they provide the same standard of service to patients. The more than 339,000 pharmacy technicians the PTCB has certified since its 1995 inception places its testing system in a position to be a nationwide benchmark.

 

 

According to a poll that the PTCB commissioned in 2007, 91% of American consumers support strong, nationwide regulations to require training and certification of pharmacy techs. And since April 1, the test has been offered in an online, on-demand format, prompting 6,800 pharmacy technicians to apply between then and the beginning of this month. Not only that, but Walgreens became a proponent of the PTCB’s testing and accreditation process early on, giving it a big-name advocate.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

J&J: Agreements with Schering-Plough void after Merck merger

BY Alaric DeArment

NEW BRUNSWICK, N.J. The planned merger between Schering-Plough Corp. and Merck & Co. would permit the termination of agreements between Schering-Plough and Johnson & Johnson’s biotech division, J&J asserted in an arbitration demand filed Wednesday with the American Arbitration Association, an alternative dispute resolution organization.

The drug maker said the planned merger constituted a change of control that would allow the termination between agreements its Centocor Ortho Biotech division made with Schering-Plough regarding the inflammatory and immunological disease drugs Remicade (infliximab) and Simponi (golimumab).

“As its public statements have made clear, Merck is acquiring Schering-Plough,” J&J said in a statement. “The acquisition constitutes a change of control that tribbers the right of our Centocor Ortho Biotech subsidiary to terminate the agreements.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

FDA accepts approval application from Warner Chilcott

BY Alaric DeArment

ARDEE, Ireland The Food and Drug Administration has accepted an approval application for a low-dose oral contraceptive from Warner Chilcott, the drug maker announced Wednesday.

The agency accepted Warner Chilcott’s new drug application for WC 3016, submitted through a subsidiary on March 26.

The company recently relocated its headquarters from Bermuda to Ireland.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?